Prothena Corporation plc
NASDAQ:PRTA
| Market Cap (Intraday) | 950.36M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $17.35 |
| 50-Day MA | $20.13 |
| 200-Day MA | $24.09 |
Prothena Corporation plc Stock, NASDAQ:PRTA
77 Sir John Rogersons Quay, Grand Canal Docklands, Dublin, Dublin 2
Ireland
Phone: +353.1.236.2500
Number of Employees: 173
Description
Prothena Corp. Plc is a clinical-stage neuroscience company, which engages in the discovery and development of novel therapies to change the course of devastating diseases. The firm�s clinical pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer�s disease, Parkinson�s disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.